China’s Clover Biopharmaceuticals Ltd. (02197.HK) was finally looking to the future after a big bet on Covid vaccines failed to pay off. However, decisions made early on in the pandemic are still casting a long shadow.
曾经风光无限的“疫苗明星股”三叶草生物制药有限公司（2197.HK），在经历新冠疫苗商业化失利、裁员近50%后，近期因遭manbetx app苹果 疫苗免疫联盟（Gavi）追讨2.24亿美元预付款，再次被推上风口浪尖。
您已阅读4%（316字），剩余96%（7834字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。